GO:0051916 granulocyte colony-stimulating factor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0051916 granulocyte colony-stimulating factor binding is a molecular_function term defined as binding to granulocyte colony-stimulating factor (G-CSF).
• G-CSF is a cytokine that regulates granulopoiesis and neutrophil function, and its binding to the receptor CSF3R initiates signaling.
• The interaction between G-CSF and CSF3R is critical for neutrophil production, and mutations in CSF3R are linked to severe congenital neutropenia and leukemia.
• G-CSF binding has been explored for therapeutic applications in regenerative medicine, including cardio- and cerebrovascular repair.
• Research methods to study G-CSF binding include surface plasmon resonance, isothermal titration calorimetry, and cell-based assays.
• CRISPR-based models, such as CSF3R knockout or point mutations, are valuable for dissecting the functional consequences of G-CSF binding.
Description
Granulocyte colony-stimulating factor (G-CSF) is a cytokine that plays a central role in the proliferation, differentiation, and survival of neutrophil precursors. The binding of G-CSF to its receptor, CSF3R, is a key molecular event that triggers intracellular signaling cascades essential for granulopoiesis. The Gene Ontology term GO:0051916, granulocyte colony-stimulating factor binding, describes the molecular function of selectively interacting with G-CSF. This term is important for researchers studying hematopoiesis, immune regulation, and therapeutic applications of G-CSF. Understanding the structural and functional aspects of G-CSF binding can inform the development of biologics and small molecules targeting this pathway.
granulocyte colony-stimulating factor binding At A Glance
| GO ID | GO:0051916 |
|---|---|
| GO term | granulocyte colony-stimulating factor binding |
| Ontology | molecular_function |
| Synonym | G-CSF binding, granulocyte colony stimulating factor binding |
| Major function | Binding to granulocyte colony-stimulating factor (G-CSF), initiating signaling through CSF3R |
| Related receptor | CSF3R (G-CSF receptor) |
| Physiological role | Regulation of granulopoiesis and neutrophil homeostasis |
| Therapeutic relevance | G-CSF is used clinically to treat neutropenia and mobilize hematopoietic stem cells |
What Is GO:0051916?
Granulocyte colony-stimulating factor binding (GO:0051916) is a molecular function defined as the selective interaction with granulocyte colony-stimulating factor (G-CSF), a cytokine also known as colony-stimulating factor 3 (CSF3). This binding event is typically mediated by the G-CSF receptor (CSF3R) and is a prerequisite for receptor activation and downstream signaling.
Why Is granulocyte colony-stimulating factor binding Important in Cell Biology?
The binding of G-CSF to its receptor is a critical step in the regulation of neutrophil production and function, and dysregulation of this pathway is associated with severe congenital neutropenia and leukemia. Moreover, G-CSF binding has been implicated in cardioprotective and neuroprotective effects, making it a target for regenerative medicine. Understanding the molecular details of this interaction can aid in the design of improved G-CSF variants and receptor antagonists.
• Essential for neutrophil development and innate immunity.
• Mutations in CSF3R, the receptor for G-CSF, cause severe congenital neutropenia and predispose to leukemia.
• G-CSF is used therapeutically to treat neutropenia and to mobilize hematopoietic stem cells for transplantation.
• G-CSF binding has been explored for cardio- and cerebrovascular regenerative applications.
• Engineered G-CSF variants with enhanced stability or affinity are of biotechnological interest.
• G-CSF signaling modulates myeloid-derived suppressor cells in cancer.
• Autophagy mediates G-CSF-induced anti-apoptotic effects in diabetic cardiomyopathy.
• G-CSF protects against acute systemic alphavirus disease in a type I IFN-dependent manner.
Molecular Mechanism of granulocyte colony-stimulating factor binding
G-CSF Structure and Receptor Recognition
In simple terms: G-CSF is a small protein that binds to a specific receptor on the surface of target cells.
G-CSF is a four-helix bundle cytokine that binds to the extracellular domain of its receptor, CSF3R, with high affinity. The binding interface involves residues from helices A and D of G-CSF and the immunoglobulin-like and cytokine receptor homology domains of CSF3R. This interaction is the first step in receptor dimerization and activation.
Receptor Dimerization and Activation
In simple terms: When G-CSF binds, two receptor molecules come together and turn on signaling inside the cell.
Binding of G-CSF to CSF3R induces receptor dimerization, which brings the intracellular domains into close proximity, allowing activation of associated Janus kinases (JAKs). Activated JAKs phosphorylate tyrosine residues on the receptor, creating docking sites for SH2-domain-containing proteins such as STAT3, which then translocate to the nucleus to regulate gene expression.
Signal Transduction Pathways
In simple terms: The activated receptor sends signals that tell the cell to grow, survive, and differentiate.
G-CSF binding activates multiple signaling pathways, including JAK/STAT, PI3K/AKT, and MAPK/ERK. These pathways collectively promote granulocytic differentiation, proliferation, and survival. Dysregulation of these pathways can lead to leukemic transformation, as seen in severe congenital neutropenia.
Regulation of G-CSF Binding
In simple terms: The strength and duration of G-CSF binding can be controlled by various factors.
The binding of G-CSF to CSF3R can be modulated by receptor shedding, internalization, and negative feedback mechanisms such as SOCS proteins. Additionally, engineered G-CSF variants with altered binding kinetics have been developed for therapeutic purposes.
Key Genes Involved in GO:0051916 granulocyte colony-stimulating factor binding
The following genes and proteins are directly involved in granulocyte colony-stimulating factor binding and its downstream signaling.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CSF3 | Encodes G-CSF, the ligand that binds to CSF3R | Target for recombinant protein production and engineering |
| CSF3R | Encodes the G-CSF receptor, which binds G-CSF | Mutations cause severe congenital neutropenia; target for CRISPR knockout |
| JAK1 | Janus kinase 1, mediates signaling downstream of CSF3R | Involved in cytokine signaling; potential therapeutic target |
| JAK2 | Janus kinase 2, mediates signaling downstream of CSF3R | Mutations in JAK2 are linked to myeloproliferative neoplasms |
| STAT3 | Signal transducer and activator of transcription 3, downstream effector | Key mediator of G-CSF-induced gene expression |
| STAT5 | Signal transducer and activator of transcription 5, downstream effector | Regulates proliferation and differentiation |
| PIK3CA | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha | Part of PI3K pathway activated by G-CSF |
| AKT1 | AKT serine/threonine kinase 1, survival signaling | Promotes cell survival downstream of G-CSF |
| MAPK1 | Mitogen-activated protein kinase 1, proliferation signaling | Involved in G-CSF-induced proliferation |
| MAPK3 | Mitogen-activated protein kinase 3, proliferation signaling | Involved in G-CSF-induced proliferation |
| SOCS3 | Suppressor of cytokine signaling 3, negative feedback | Regulates G-CSF signaling duration |
| CEBPB | CCAAT/enhancer-binding protein beta, transcription factor | Regulates myeloid-derived suppressor cells in cancer |
| LYN | LYN proto-oncogene, Src family tyrosine kinase | May modulate G-CSF receptor signaling |
| PTPN11 | Protein tyrosine phosphatase non-receptor type 11 (SHP2) | Regulates JAK/STAT pathway downstream of CSF3R |
| CSF3R (isoform) | Alternatively spliced isoform of G-CSF receptor | Altered signaling in neutropenia |
| G-CSF (recombinant) | Engineered G-CSF variants | Enhanced stability for therapeutic use |
| CSF3R nanobody | Engineered nanobody against CSF3R | Improved affinity for research and therapy |
How Is granulocyte colony-stimulating factor binding Regulated?
The binding of G-CSF to its receptor is regulated at multiple levels. Receptor expression can be modulated by cytokines and transcription factors. Negative feedback mechanisms, such as SOCS3, attenuate signaling to prevent excessive neutrophil production. Additionally, the stability and activity of G-CSF itself can be engineered for improved therapeutic properties.
granulocyte colony-stimulating factor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CSF3R | Severe congenital neutropenia | Knockout or point mutation in hematopoietic stem cells |
| CSF3R | Acute myeloid leukemia | Knock-in of truncated CSF3R in mouse models |
| CSF3 | Neutropenia (therapeutic use) | Overexpression of G-CSF in cell lines |
| CEBPB | Triple-negative breast cancer | Knockout in cancer cell lines to study MDSC function |
| CSF3R | Alphavirus disease | Knockout mice to study G-CSF protection |
Severe Congenital Neutropenia
Mutations in CSF3R, the receptor for G-CSF, are a major cause of severe congenital neutropenia, a disorder characterized by a lack of neutrophils and increased susceptibility to infections. These mutations often affect the extracellular domain of CSF3R, impairing G-CSF binding and downstream signaling.
Leukemia
Patients with severe congenital neutropenia have a predisposition to develop acute myeloid leukemia, often associated with acquired mutations in CSF3R that lead to truncated receptors and enhanced proliferative signaling. Understanding G-CSF binding and receptor activation is crucial for developing targeted therapies.
Cardiovascular and Cerebrovascular Diseases
G-CSF has been investigated for its regenerative effects in cardio- and cerebrovascular diseases, where it may promote angiogenesis and neuroprotection. The binding of G-CSF to its receptor on endothelial and neural cells is thought to mediate these effects.
Diabetic Cardiomyopathy
G-CSF has been shown to exert anti-apoptotic effects in diabetic cardiomyopathy through the induction of autophagy. The binding of G-CSF to its receptor activates signaling pathways that protect cardiomyocytes from apoptosis.
From granulocyte colony-stimulating factor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of CSF3R knockout on neutrophil development? | CSF3R knockout mice or human iPSC-derived neutrophils |
| How do point mutations in CSF3R affect G-CSF binding affinity? | CRISPR point-mutation knock-in in cell lines |
| Can engineered G-CSF variants with enhanced stability improve neutropenia treatment? | Knock-in of mutant CSF3 in mice |
| What is the role of CEBPB in G-CSF-mediated MDSC expansion? | CEBPB knockout in triple-negative breast cancer models |
| Does G-CSF protect against alphavirus infection? | CSF3 knockout mice |
| How does G-CSF binding affect autophagy in diabetic cardiomyopathy? | Cardiomyocyte-specific CSF3R knockout mice |
How to Study the granulocyte colony-stimulating factor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Surface plasmon resonance | Binding kinetics (kon, koff) and affinity (KD) | Characterizing G-CSF-CSF3R interaction |
| Isothermal titration calorimetry | Binding affinity, enthalpy, stoichiometry | Evaluating engineered G-CSF variants |
| Western blot | Phosphorylation of STAT3, AKT, ERK | Assessing downstream signaling |
| Proliferation assay | Cell growth and viability | Functional response to G-CSF |
| Flow cytometry | Receptor expression and binding | Quantifying cell surface CSF3R |
| CRISPR knockout | Gene function | Identifying genes required for G-CSF binding |
| RNA-seq | Transcriptional changes | Global effects of G-CSF signaling |
| Autophagy flux assay | Autophagic activity | Studying G-CSF-induced autophagy |
Surface Plasmon Resonance (SPR)
SPR is used to measure the binding kinetics and affinity between G-CSF and its receptor or engineered variants. This label-free method provides real-time association and dissociation rates, which are critical for understanding the strength of the interaction.
Isothermal Titration Calorimetry (ITC)
ITC measures the heat released or absorbed upon binding, allowing determination of binding affinity, enthalpy, and stoichiometry. It is valuable for characterizing engineered G-CSF variants with altered binding properties.
Cell-Based Signaling Assays
Cell-based assays, such as STAT3 phosphorylation and proliferation assays, are used to assess the functional consequences of G-CSF binding. These assays can be performed with wild-type or mutant receptors to dissect signaling pathways.
CRISPR Screening
Genome-wide CRISPR screens can identify genes that modulate G-CSF binding and signaling. Such screens have revealed novel regulators of the G-CSF pathway and potential therapeutic targets.
How CRISPR Can Be Used to Study GO:0051916 granulocyte colony-stimulating factor binding
Knockout
CRISPR knockout of CSF3R or downstream signaling genes (e.g., JAK2, STAT3) can abolish G-CSF binding and signaling, providing insights into the pathway's role in neutrophil development and disease. Knockout models are also used to validate drug targets.
Point Mutation
Point mutations in CSF3R identified in severe congenital neutropenia can be introduced using CRISPR to study their effects on G-CSF binding affinity and receptor function. Such models help elucidate genotype-phenotype relationships.
Knock-in
Knock-in of engineered G-CSF variants or tagged receptors allows for precise tracking and functional analysis. For example, a knock-in of a stabilized G-CSF variant can be used to test its therapeutic potential in vivo.
Overexpression
Overexpression of G-CSF or CSF3R in cell lines can be used to study ligand-receptor interactions and downstream signaling in a controlled setting. This approach is useful for biochemical and structural studies.
How EDITGENE Supports granulocyte colony-stimulating factor binding Research
Researchers studying granulocyte colony-stimulating factor binding-related genes often need to determine whether a candidate gene is causally involved in the pathway or is merely a bystander. EDITGENE provides a comprehensive suite of CRISPR services to enable precise genetic modifications in relevant cell models.
Contact EDITGENE today to design your custom CRISPR model for granulocyte colony-stimulating factor binding research.
Frequently Asked Questions About granulocyte colony-stimulating factor binding
What is granulocyte colony-stimulating factor binding?
Granulocyte colony-stimulating factor binding (GO:0051916) is a molecular function defined as the selective interaction with G-CSF, a cytokine that regulates neutrophil production.
What genes are involved in granulocyte colony-stimulating factor binding?
The primary genes are CSF3 (encoding G-CSF) and CSF3R (encoding the G-CSF receptor), along with downstream signaling genes such as JAK2, STAT3, and STAT5.
What diseases are associated with defects in G-CSF binding?
Defects in G-CSF binding are associated with severe congenital neutropenia and an increased risk of leukemia.
How is G-CSF binding studied experimentally?
G-CSF binding is studied using methods such as surface plasmon resonance, isothermal titration calorimetry, and cell-based signaling assays.
What is the role of CSF3R in G-CSF binding?
CSF3R is the receptor for G-CSF; binding of G-CSF to CSF3R triggers receptor dimerization and activation of JAK/STAT signaling.
Can CRISPR be used to study G-CSF binding?
Yes, CRISPR knockout, point mutation, and knock-in models are powerful tools to dissect the G-CSF binding pathway and its role in disease.
What are the therapeutic applications of G-CSF?
G-CSF is used clinically to treat neutropenia and to mobilize hematopoietic stem cells, and it is being explored for regenerative applications in cardio- and cerebrovascular diseases.
How does G-CSF binding affect autophagy?
G-CSF binding can induce autophagy, which mediates anti-apoptotic effects in diabetic cardiomyopathy.
What is the link between G-CSF and cancer?
G-CSF signaling can modulate myeloid-derived suppressor cells and has been implicated in tumor immunity, particularly in triple-negative breast cancer.
What model systems are available to study G-CSF binding?
Model systems include knockout mice, human iPSC-derived neutrophils, and CRISPR-engineered cell lines.
Conclusion
Granulocyte colony-stimulating factor binding (GO:0051916) is a fundamental molecular function that governs neutrophil development and immune responses. Dysregulation of this interaction leads to severe congenital neutropenia and leukemia, and it holds promise for regenerative medicine. Advanced research methods, including CRISPR-based models and biophysical techniques, continue to unravel the intricacies of G-CSF binding, offering new avenues for therapeutic intervention.
References
- 1. Skokowa J et al.. 2017. Severe congenital neutropenias.. Nat Rev Dis Primers 3:17032 PMID: 28593997
- 2. Hameed M et al.. 2025. Granulocyte colony-stimulating factor protects against acute systemic alphavirus disease in a type I IFN-dependent manner.. Front Immunol 16:1606053 PMID: 40718486
- 3. Nicola NA. 1990. Granulocyte colony-stimulating factor.. Immunol Ser 49:77-109 PMID: 1708682
- 4. Li W et al.. 2018. Aerobic Glycolysis Controls Myeloid-Derived Suppressor Cells and Tumor Immunity via a Specific CEBPB Isoform in Triple-Negative Breast Cancer.. Cell Metab 28(1):87-103.e6 PMID: 29805099
- 5. Bakherad H et al.. 2020. Engineering an anti-granulocyte colony stimulating factor receptor nanobody for improved affinity.. Life Sci 257:118052 PMID: 32634431
- 6. Shen GY et al.. 2021. Role of Autophagy in Granulocyte-Colony Stimulating Factor Induced Anti-Apoptotic Effects in Diabetic Cardiomyopathy.. Diabetes Metab J 45(4):594-605 PMID: 33631916
- 7. Klocke R et al.. 2008. Granulocyte colony-stimulating factor (G-CSF) for cardio- and cerebrovascular regenerative applications.. Curr Med Chem 15(10):968-77 PMID: 18393854
- 8. Bishop B et al.. 2001. Reengineering granulocyte colony-stimulating factor for enhanced stability.. J Biol Chem 276(36):33465-70 PMID: 11406632
